| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
60,850,000 |
| Market
Cap: |
5.84(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.05 - $0.096 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are vital to normal and effective function of the brain and nervous system. Co. is developing a pipeline of product candidates derived from its NMDAr modulator discovery platform, or the discovery platform: NYX-2925 for the treatment of chronic pain; NYX-783 for the treatment of post-traumatic stress disorder; and NYX-458 for the treatment of cognitive impairment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moskal Joseph R. |
Chief Scientific Officer |
• – – |
2018-06-25 |
4 |
B |
$16.00 |
$48,000 |
D/D |
3,000 |
378,288 |
2.74 |
- |
|
| Moskal Joseph R. |
Chief Scientific Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
24,689 |
375,288 |
|
- |
|
| Houck David |
Chief Development Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,328 |
36,924 |
|
- |
|
| Madsen Torsten M. |
Chief Medical Officer |
• – – |
2018-06-25 |
4 |
B |
$16.00 |
$16,000 |
D/D |
1,000 |
231,550 |
2.74 |
- |
|
| Madsen Torsten M. |
Chief Medical Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,789 |
230,550 |
|
- |
|
| Riedel Norbert G |
CEO and President |
• • – |
2018-06-25 |
4 |
B |
$16.00 |
$38,400 |
I/I |
2,400 |
5,118 |
2.66 |
- |
|
| Riedel Norbert G |
CEO and President |
• • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,718 |
2,718 |
|
- |
|
| Riedel Norbert G |
CEO and President |
• • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
116,481 |
323,976 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2018-06-25 |
4 |
B |
$16.00 |
$385,600 |
D/D |
24,100 |
24,100 |
2.39 |
- |
|
| Longitude Venture Partners Ii, L.p. |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
3,190,079 |
1.5 |
- |
|
| Longitude Venture Partners Ii, L.p. |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
3,040,079 |
|
- |
|
| Heron Patrick J |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
D/D |
150,000 |
3,190,079 |
2.45 |
- |
|
| Heron Patrick J |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,040,079 |
3,040,079 |
|
- |
|
| Kidd Andrew |
Chief Commercial Officer |
• – – |
2018-06-25 |
4 |
B |
$16.00 |
$107,200 |
D/D |
6,700 |
9,133 |
2.74 |
- |
|
| Kidd Andrew |
Chief Commercial Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,433 |
2,433 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
3,190,079 |
2.1 |
- |
|
| Enright Patrick G |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
3,040,079 |
|
- |
|
| Gantz Wilbur H |
Director |
– • – |
2018-06-25 |
4 |
B |
$16.00 |
$369,600 |
I/I |
23,100 |
80,167 |
2.1 |
- |
|
| Gantz Wilbur H |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
320,959 |
74,067 |
|
- |
|
69 Records found
|
|
Page 3 of 3 |
|
|
